| Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
|---|
| Doxapram | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | | Doxapram | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | | Doxapram | hsa00071 | Fatty acid degradation | 3.50E-02 | 4 | O75521, P00325, P11766, P33121 | ECI2, ADH1B, ADH5, ACSL1 | More | | | Doxapram | hsa00072 | Synthesis and degradation of ketone bodies | 2.78E-02 | 1 | Q01581 | HMGCS1 | More | | | Doxapram | hsa00190 | Oxidative phosphorylation | 1.28E-05 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | | Doxapram | hsa00310 | Lysine degradation | 3.15E-02 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | | | Doxapram | hsa00350 | Tyrosine metabolism | 3.40E-02 | 1 | P28332 | ADH6 | More | | | Doxapram | hsa00500 | Starch and sucrose metabolism | 5.14E-04 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | | Doxapram | hsa00520 | Amino sugar and nucleotide sugar metabolism | 2.24E-02 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | | Doxapram | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | | Doxapram | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | | Doxapram | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | | Doxapram | hsa00600 | Sphingolipid metabolism | 2.44E-02 | 2 | Q9BX95, Q06136 | SGPP1, FVT1 | More | | | Doxapram | hsa00630 | Glyoxylate and dicarboxylate metabolism | 1.13E-02 | 2 | P40925, P15104 | MDH1, GLUL | More | | | Doxapram | hsa00730 | Thiamine metabolism | 3.03E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | | | Doxapram | hsa00760 | Nicotinate and nicotinamide metabolism | 3.52E-02 | 1 | P21589 | NT5E | More | | | Doxapram | hsa00770 | Pantothenate and CoA biosynthesis | 2.26E-04 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | | Doxapram | hsa00785 | Lipoic acid metabolism | 4.32E-02 | 1 | Q9Y234 | LIPT1 | More | | | Doxapram | hsa00830 | Retinol metabolism | 1.16E-04 | 4 | P00325, P11766, Q9BPW9, O75911 | ADH1B, ADH5, DHRS9, DHRS3 | More | | | Doxapram | hsa00900 | Terpenoid backbone biosynthesis | 1.40E-02 | 1 | Q01581 | HMGCS1 | More | | | Doxapram | hsa00970 | Aminoacyl-tRNA biosynthesis | 1.92E-04 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | | Doxapram | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 8.40E-04 | 3 | P78417, P28332, P11712 | GSTO1, ADH6, CYP2C9 | More | | | Doxapram | hsa00982 | Drug metabolism - cytochrome P450 | 8.40E-04 | 3 | P11712, P78417, P28332 | CYP2C9, GSTO1, ADH6 | More | | | Doxapram | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | | Doxapram | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | | Doxapram | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | | Doxapram | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 2.18E-02 | 2 | P49841, Q9NRA1 | GSK3B, PDGFC | More | | | Doxapram | hsa01522 | Endocrine resistance | 4.74E-02 | 3 | P22694, P10415, Q13323 | PRKACB, BCL2, BIK | More | | | Doxapram | hsa01523 | Antifolate resistance | 1.43E-03 | 2 | Q92820, P04818 | GGH, TYMS | More | | | Doxapram | hsa02010 | ABC transporters | 1.66E-04 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | | | Doxapram | hsa03013 | RNA transport | 8.19E-04 | 7 | Q15287, Q9UBU9, P35658, P63279, P55884, O15371, P20042 | RNPS1, NXF1, NUP214, UBE2I, EIF3B, EIF3D, EIF2S2 | More | | | Doxapram | hsa03015 | mRNA surveillance pathway | 1.83E-02 | 3 | Q13362, Q14738, Q9UBU9 | PPP2R5C, PPP2R5D, NXF1 | More | | | Doxapram | hsa03020 | RNA polymerase | 1.31E-02 | 2 | P24928, P62487 | POLR2A, POLR2G | More | | | Doxapram | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | | Doxapram | hsa03040 | Spliceosome | 2.37E-06 | 18 | Q14562, O43143, O60508, P08579, Q15427, P26368, O75940, P38159, P61978, O75494, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O75643 | DHX8, DHX15, CDC40, SNRPB2, SF3B4, U2AF2, SMNDC1, RBMX, HNRPK, FUSIP1, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, ASCC3L1 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Q14562 | DHX8 | ATP-dependent RNA helicase DHX8 | -0.853 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | O43143 | DHX15 | ATP-dependent RNA helicase DHX15 | -0.818 | | P07948 | LYN | Tyrosine-protein kinase Lyn | O60508 | CDC40 | Pre-mRNA-processing factor 17 | -0.814 | | P07948 | LYN | Tyrosine-protein kinase Lyn | P08579 | SNRPB2 | U2 small nuclear ribonucleoprotein B'' | -0.739 | | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Q15427 | SF3B4 | Splicing factor 3B subunit 4 | 0.71 | | P07948 | LYN | Tyrosine-protein kinase Lyn | P26368 | U2AF2 | Splicing factor U2AF 65 kDa subunit | -0.775 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | O75940 | SMNDC1 | Survival of motor neuron-related-splicing factor 30 | 0.786 | | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | P38159 | RBMX | RNA-binding motif protein, X chromosome | 0.733 | | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | P61978 | HNRPK | Heterogeneous nuclear ribonucleoprotein K | 0.784 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | O75494 | FUSIP1 | Serine/arginine-rich splicing factor 10 | 0.73 | | P07948 | LYN | Tyrosine-protein kinase Lyn | Q13595 | TRA2A | Transformer-2 protein homolog alpha | -0.742 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Q07955 | SFRS1 | Serine/arginine-rich splicing factor 1 | -0.776 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Q01130 | SFRS2 | Serine/arginine-rich splicing factor 2 | -0.758 | | P07948 | LYN | Tyrosine-protein kinase Lyn | Q01130 | SFRS2 | Serine/arginine-rich splicing factor 2 | -0.716 | | P07948 | LYN | Tyrosine-protein kinase Lyn | P84103 | SFRS3 | Serine/arginine-rich splicing factor 3 | -0.79 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Q13243 | SFRS5 | Serine/arginine-rich splicing factor 5 | -0.87 | | P07948 | LYN | Tyrosine-protein kinase Lyn | Q13243 | SFRS5 | Serine/arginine-rich splicing factor 5 | -0.781 | | P07948 | LYN | Tyrosine-protein kinase Lyn | P11142 | HSPA8 | Heat shock cognate 71 kDa protein | -0.732 | | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | P11142 | HSPA8 | Heat shock cognate 71 kDa protein | 0.766 | | P07948 | LYN | Tyrosine-protein kinase Lyn | Q9Y2W2 | WBP11 | WW domain-binding protein 11 | -0.734 | | P07948 | LYN | Tyrosine-protein kinase Lyn | O75643 | ASCC3L1 | U5 small nuclear ribonucleoprotein 200 kDa helicase | -0.742 |
| | Doxapram | hsa03050 | Proteasome | 4.83E-02 | 1 | P55036 | PSMD4 | More | | | Doxapram | hsa03060 | Protein export | 1.43E-02 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | | | Doxapram | hsa03450 | Non-homologous end-joining | 3.17E-03 | 2 | Q9NP87, P13010 | POLM, XRCC5 | More | | | Doxapram | hsa04012 | ErbB signaling pathway | 3.74E-02 | 3 | P21860, Q13557, O14944 | ERBB3, CAMK2D, EREG | More | | | Doxapram | hsa04014 | Ras signaling pathway | 1.70E-02 | 7 | P20827, Q9NRA1, P49767, P17252, P0DP23, P62873, P19174 | EFNA1, PDGFC, VEGFC, PRKCA, CALM1, GNB1, PLCG1 | More | | | Doxapram | hsa04015 | Rap1 signaling pathway | 4.58E-02 | 6 | P20827, Q9NRA1, P49767, P0DP23, P17252, P19174 | EFNA1, PDGFC, VEGFC, CALM1, PRKCA, PLCG1 | More | | | Doxapram | hsa04020 | Calcium signaling pathway | 7.55E-05 | 12 | Q96DU7, P45880, Q13557, P17252, P21860, P19174, P0DP23, P51828, P20020, P23634, Q9NRA1, P49767 | ITPKC, VDAC2, CAMK2D, PRKCA, ERBB3, PLCG1, CALM1, ADCY7, ATP2B1, ATP2B4, PDGFC, VEGFC | More | | | Doxapram | hsa04022 | cGMP-PKG signaling pathway | 4.72E-02 | 4 | Q99941, P23634, P51828, P45880 | CREBL1, ATP2B4, ADCY7, VDAC2 | More | | | Doxapram | hsa04060 | Cytokine-cytokine receptor interaction | 4.71E-02 | 2 | P78552, O75509 | IL13RA1, TNFRSF21 | More | | | Doxapram | hsa04062 | Chemokine signaling pathway | 3.93E-03 | 10 | P25024, P25025, P47992, Q9UBD3, P07948, P63218, P50151, P49407, Q08881, P49841 | CXCR1, CXCR2, XCL1, XCL2, LYN, GNG5, GNG10, ARRB1, ITK, GSK3B | More | | | Doxapram | hsa04064 | NF-kappa B signaling pathway | 1.01E-03 | 12 | O00463, P14778, P01584, P01375, Q04759, Q13077, Q16548, P06239, Q8WV28, P24522, P09341, Q9NQC7 | TRAF5, IL1R1, IL1B, TNF, PRKCQ, TRAF1, BCL2A1, LCK, BLNK, GADD45A, CXCL1, CYLD | More | | | Doxapram | hsa04070 | Phosphatidylinositol signaling system | 4.40E-02 | 4 | P19174, P0DP23, P23743, P17252 | PLCG1, CALM1, DGKA, PRKCA | More | | | Doxapram | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 4 | P21453, Q9H228, P01375, Q13362 | S1PR1, EDG8, TNF, PPP2R5C | More | | | Doxapram | hsa04072 | Phospholipase D signaling pathway | 9.70E-03 | 2 | Q92529, Q14344 | SHC3, GNA13 | More | | | Doxapram | hsa04080 | Neuroactive ligand-receptor interaction | 4.76E-05 | 10 | P08311, P28472, Q15722, P21453, Q9H228, O00398, Q01726, P41968, P21730, P07550 | CTSG, GABRB3, LTB4R, S1PR1, EDG8, P2RY10, MC1R, MC3R, C5AR1, ADRB2 | More | | | Doxapram | hsa04110 | Cell cycle | 1.97E-05 | 7 | P06493, O60566, O75293, P30304, P33981, P42773, P01106 | CDK1, BUB1B, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | | | Doxapram | hsa04114 | Oocyte meiosis | 1.25E-03 | 7 | P51812, Q02750, P0DP23, P16298, Q17RY0, Q13362, Q14738 | RPS6KA3, MAP2K1, CALM1, PPP3CB, CPEB4, PPP2R5C, PPP2R5D | More | | | Doxapram | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | | Doxapram | hsa04140 | Autophagy - animal | 4.74E-02 | 3 | P22694, Q14643, P10415 | PRKACB, ITPR1, BCL2 | More | | | Doxapram | hsa04141 | Protein processing in endoplasmic reticulum | 3.64E-02 | 5 | Q99941, O75460, P11142, Q9H3Z4, P07900 | CREBL1, ERN1, HSPA8, DNAJC5, HSP90AA1 | More | | | Doxapram | hsa04144 | Endocytosis | 1.24E-02 | 9 | Q13191, P11142, O75351, P62491, P25024, P43250, Q14161, P14784, Q9Y5X3 | CBLB, HSPA8, VPS4B, RAB11A, CXCR1, GRK6, GIT2, IL2RB, SNX5 | More | | | Doxapram | hsa04145 | Phagosome | 4.68E-02 | 5 | Q15080, P14598, Q13509, P68371, Q13488 | NCF4, NCF1, TUBB3, TUBB2C, TCIRG1 | More | | | Doxapram | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | | | Doxapram | hsa04152 | AMPK signaling pathway | 1.83E-02 | 3 | Q96RR4, Q13362, Q14738 | CAMKK2, PPP2R5C, PPP2R5D | More | | | Doxapram | hsa04217 | Necroptosis | 8.52E-07 | 13 | P01375, P01568, P48023, Q13489, Q13546, P42224, Q14765, P08238, Q6FI13, Q99878, Q93077, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, RIPK1, STAT1, STAT4, HSP90AB1, H2AC18; H2AC19, H2AC14, HIST1H2AC, CHMP2A, PPID | More | | | Doxapram | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | | | Doxapram | hsa04261 | Adrenergic signaling in cardiomyocytes | 4.15E-04 | 10 | P07550, P51828, P22694, Q99941, P18848, Q13362, Q14738, P0DP23, Q13557, P23634 | ADRB2, ADCY7, PRKACB, CREBL1, ATF4, PPP2R5C, PPP2R5D, CALM1, CAMK2D, ATP2B4 | More | | | Doxapram | hsa04330 | Notch signaling pathway | 4.34E-02 | 2 | Q92542, P46531 | NCSTN, NOTCH1 | More | | | Doxapram | hsa04340 | Hedgehog signaling pathway | 9.74E-03 | 3 | P22694, Q13635, P10415 | PRKACB, PTCH1, BCL2 | More | | | Doxapram | hsa04360 | Axon guidance | 2.29E-02 | 5 | P16333, P20827, O95631, P17252, P19174 | NCK1, EFNA1, NTN1, PRKCA, PLCG1 | More | | | Doxapram | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | | Doxapram | hsa04380 | Osteoclast differentiation | 2.05E-03 | 12 | Q9NQC7, Q9UQC2, Q16539, P23458, P06239, P01584, P14778, O75015, Q8WV28, P01375, Q15080, P78324 | CYLD, GAB2, MAPK14, JAK1, LCK, IL1B, IL1R1, FCGR3B, BLNK, TNF, NCF4, SIRPA | More | | | Doxapram | hsa04390 | Hippo signaling pathway | 5.79E-03 | 4 | P04628, Q9UJU2, O43623, Q13489 | WNT1, LEF1, SNAI2, BIRC3 | More | | | Doxapram | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | | Doxapram | hsa04540 | Gap junction | 1.19E-03 | 6 | P17252, P22694, Q13509, P68371, Q9NRA1, Q14643 | PRKCA, PRKACB, TUBB3, TUBB2C, PDGFC, ITPR1 | More | | | Doxapram | hsa04610 | Complement and coagulation cascades | 3.71E-08 | 2 | P00734, P0C0L4 | F2, C4A | More | | | Doxapram | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | | Doxapram | hsa04613 | Neutrophil extracellular trap formation | 8.84E-04 | 19 | O60603, P05164, P08246, Q9UM07, Q13547, Q92769, P04908, P0C0S5, Q93077, P62807, O60814, P68431, Q15080, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AC4; H2AC8, H2AFZ, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | | Doxapram | hsa04614 | Renin-angiotensin system | 2.74E-02 | 3 | P15144, P08311, O75787 | ANPEP, CTSG, ATP6AP2 | More | | | Doxapram | hsa04623 | Cytosolic DNA-sensing pathway | 2.61E-05 | 3 | P01568, Q13546, P25963 | IFNA21, RIPK1, NFKBIA | More | | | Doxapram | hsa04625 | C-type lectin receptor signaling pathway | 8.11E-03 | 9 | Q9ULY5, P01584, Q9NQC7, P20749, Q14643, P01375, Q13191, P0DP24, Q16539 | CLEC4E, IL1B, CYLD, BCL3, ITPR1, TNF, CBLB, CALM2, MAPK14 | More | | | Doxapram | hsa04640 | Hematopoietic cell lineage | 1.98E-03 | 15 | P13612, P21926, P14778, P27930, P15144, P11836, P07766, P09693, P01732, P01730, P06127, P09564, P13765, P01375, P01584 | ITGA4, CD9, IL1R1, IL1R2, ANPEP, MS4A1, CD3E, CD3G, CD8A, CD4, CD5, CD7, HLA-DOB, TNF, IL1B | More | | | Doxapram | hsa04650 | Natural killer cell mediated cytotoxicity | 1.27E-07 | 14 | P16298, P50591, P01375, P78314, P06239, O60880, P20963, Q02750, Q13241, P26718, O75015, P26717, Q14953, P26715 | PPP3CB, TNFSF10, TNF, SH3BP2, LCK, SH2D1A, CD247, MAP2K1, KLRD1, KLRK1, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P11511 | CYP19A1 | Aromatase | P16298 | PPP3CB | Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform | 0.706 | | P11511 | CYP19A1 | Aromatase | P50591 | TNFSF10 | Tumor necrosis factor ligand superfamily member 10 | 0.701 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.761 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.823 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.788 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.727 | | P11511 | CYP19A1 | Aromatase | Q02750 | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | 0.783 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.82 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.701 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.91 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.81 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.701 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.92 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.896 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.846 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.846 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 |
| | Doxapram | hsa04657 | IL-17 signaling pathway | 2.61E-05 | 14 | P25963, P08238, O00463, Q07955, Q16539, P49841, P09341, P19875, P14780, P04141, P80188, P01375, P06702, P01584 | NFKBIA, HSP90AB1, TRAF5, SFRS1, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, CSF2, LCN2, TNF, S100A9, IL1B | More | | | Doxapram | hsa04658 | Th1 and Th2 cell differentiation | 1.07E-03 | 13 | Q04759, P07766, P20963, P09693, Q16539, P06239, Q14765, P23771, Q9UL17, P14784, P13765, P23458, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, JAK1, RUNX3 | More | | | Doxapram | hsa04659 | Th17 cell differentiation | 2.94E-04 | 15 | Q04759, Q16539, P06239, P14784, P13765, P14778, Q9UL17, P23771, Q13485, P01584, P08238, P07766, P09693, P20963, P23458 | PRKCQ, MAPK14, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, SMAD4, IL1B, HSP90AB1, CD3E, CD3G, CD247, JAK1 | More | | | Doxapram | hsa04660 | T cell receptor signaling pathway | 1.42E-04 | 17 | P01375, P04141, P25963, Q04759, P10747, O95267, Q08881, P19174, P16333, P20963, P09693, P01732, Q13191, P06239, P29350, Q16539, P49841 | TNF, CSF2, NFKBIA, PRKCQ, CD28, RASGRP1, ITK, PLCG1, NCK1, CD247, CD3G, CD8A, CBLB, LCK, PTPN6, MAPK14, GSK3B | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | P04141 | CSF2 | Granulocyte-macrophage colony-stimulating factor | 0.757 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | -0.739 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | P10747 | CD28 | T-cell-specific surface glycoprotein CD28 | 0.758 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.852 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.866 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.739 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | P16333 | NCK1 | Cytoplasmic protein NCK1 | -0.703 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.835 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.781 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.803 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.734 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | P29350 | PTPN6 | Tyrosine-protein phosphatase non-receptor type 6 | -0.797 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.883 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.795 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.812 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 |
| | Doxapram | hsa04662 | B cell receptor signaling pathway | 4.07E-02 | 4 | P42338, P60033, P07948, Q8N149 | PIK3CB, CD81, LYN, LILRA2 | More | | | Doxapram | hsa04668 | TNF signaling pathway | 4.29E-03 | 7 | P01375, Q99941, P18848, P19875, P01584, P14780, O95429 | TNF, CREBL1, ATF4, CXCL2, IL1B, MMP9, BAG4 | More | | | Doxapram | hsa04713 | Circadian entrainment | 3.32E-02 | 4 | P0DP23, P17252, P62873, O15055 | CALM1, PRKCA, GNB1, PER2 | More | | | Doxapram | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | | Doxapram | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | | | Doxapram | hsa04721 | Synaptic vesicle cycle | 3.15E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | | Doxapram | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | | Doxapram | hsa04724 | Glutamatergic synapse | 2.22E-02 | 4 | O15399, P63218, P50151, P15104 | GRIN2D, GNG5, GNG10, GLUL | More | | | Doxapram | hsa04725 | Cholinergic synapse | 3.74E-02 | 3 | P22694, Q14643, P10415 | PRKACB, ITPR1, BCL2 | More | | | Doxapram | hsa04727 | GABAergic synapse | 4.42E-02 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | | | Doxapram | hsa04728 | Dopaminergic synapse | 2.87E-03 | 9 | P14416, P63218, P50151, P49841, Q16539, P49407, Q13362, Q14738, P0DP23 | DRD2, GNG5, GNG10, GSK3B, MAPK14, ARRB1, PPP2R5C, PPP2R5D, CALM1 | More | | | Doxapram | hsa04730 | Long-term depression | 3.52E-02 | 1 | Q14344 | GNA13 | More | | | Doxapram | hsa04744 | Phototransduction | 1.18E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | | Doxapram | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.51E-03 | 9 | P14778, P01584, P51828, P22694, Q13557, Q16539, Q14643, Q04759, P0DP24 | IL1R1, IL1B, ADCY7, PRKACB, CAMK2D, MAPK14, ITPR1, PRKCQ, CALM2 | More | | | Doxapram | hsa04911 | Insulin secretion | 1.48E-02 | 3 | P51828, Q99941, Q13557 | ADCY7, CREBL1, CAMK2D | More | | | Doxapram | hsa04912 | GnRH signaling pathway | 4.33E-02 | 6 | P51828, Q16539, Q9Y6R4, Q14643, P0DP24, P22694 | ADCY7, MAPK14, MAP3K4, ITPR1, CALM2, PRKACB | More | | | Doxapram | hsa04913 | Ovarian steroidogenesis | 1.27E-03 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | | Doxapram | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | | | Doxapram | hsa04915 | Estrogen signaling pathway | 4.72E-02 | 4 | Q99941, P51828, P07900, P11142 | CREBL1, ADCY7, HSP90AA1, HSPA8 | More | | | Doxapram | hsa04916 | Melanogenesis | 2.18E-02 | 2 | P49841, Q01726 | GSK3B, MC1R | More | | | Doxapram | hsa04921 | Oxytocin signaling pathway | 3.13E-02 | 3 | P0DP23, Q96RR4, Q13469 | CALM1, CAMKK2, NFATC2 | More | | | Doxapram | hsa04924 | Renin secretion | 2.90E-04 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | | | Doxapram | hsa04925 | Aldosterone synthesis and secretion | 5.19E-03 | 4 | Q99941, P51828, Q13557, P23634 | CREBL1, ADCY7, CAMK2D, ATP2B4 | More | | | Doxapram | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | | Doxapram | hsa04927 | Cortisol synthesis and secretion | 1.27E-03 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | | | Doxapram | hsa04928 | Parathyroid hormone synthesis, secretion and action | 1.02E-02 | 4 | Q14643, P22694, P23771, P10415 | ITPR1, PRKACB, GATA3, BCL2 | More | | | Doxapram | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | | | Doxapram | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.72E-02 | 5 | P42224, Q12778, P49767, P17252, P19174 | STAT1, FOXO1, VEGFC, PRKCA, PLCG1 | More | | | Doxapram | hsa04934 | Cushing syndrome | 5.32E-04 | 7 | Q14643, Q99941, P51828, P22694, O15169, Q13557, P04628 | ITPR1, CREBL1, ADCY7, PRKACB, AXIN1, CAMK2D, WNT1 | More | | | Doxapram | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Doxapram | hsa04960 | Aldosterone-regulated sodium reabsorption | 4.38E-02 | 1 | P48048 | KCNJ1 | More | | | Doxapram | hsa04962 | Vasopressin-regulated water reabsorption | 1.80E-02 | 2 | P62491, P46459 | RAB11A, NSF | More | | | Doxapram | hsa04964 | Proximal tubule bicarbonate reclamation | 2.17E-03 | 1 | P00918 | CA2 | More | | | Doxapram | hsa04966 | Collecting duct acid secretion | 2.17E-03 | 1 | P00918 | CA2 | More | | | Doxapram | hsa04970 | Salivary secretion | 9.44E-04 | 4 | P07550, P22694, Q14643, P49913 | ADRB2, PRKACB, ITPR1, CAMP | More | | | Doxapram | hsa04971 | Gastric acid secretion | 1.48E-02 | 3 | P51828, P15311, Q13557 | ADCY7, VIL2, CAMK2D | More | | | Doxapram | hsa04972 | Pancreatic secretion | 1.31E-02 | 2 | Q08828, P62491 | ADCY1, RAB11A | More | | | Doxapram | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | | Doxapram | hsa04979 | Cholesterol metabolism | 1.61E-02 | 2 | P38571, P61916 | LIPA, NPC2 | More | | | Doxapram | hsa05010 | Alzheimer disease | 2.07E-02 | 7 | Q92542, P05496, P12074, O75460, P01584, O15169, P45880 | NCSTN, ATP5G1, COX6A1, ERN1, IL1B, AXIN1, VDAC2 | More | | | Doxapram | hsa05012 | Parkinson disease | 3.12E-02 | 6 | Q16718, O14521, P19174, P0DP23, Q13509, P68371 | NDUFA5, SDHD, PLCG1, CALM1, TUBB3, TUBB2C | More | | | Doxapram | hsa05017 | Spinocerebellar ataxia | 2.22E-02 | 4 | Q92915, O15399, P42338, P21796 | FGF14, GRIN2D, PIK3CB, VDAC1 | More | | | Doxapram | hsa05020 | Prion disease | 1.01E-04 | 13 | P01584, P46531, P11142, Q16718, O14521, P05496, P12074, Q92736, P45880, O60282, P49841, Q99941, Q16539 | IL1B, NOTCH1, HSPA8, NDUFA5, SDHD, ATP5G1, COX6A1, RYR2, VDAC2, KIF5C, GSK3B, CREBL1, MAPK14 | More | | | Doxapram | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.14E-03 | 11 | Q13509, P68371, P49841, Q16718, O14521, Q13561, P19174, P17252, Q16539, Q08752, P0DP23 | TUBB3, TUBB2C, GSK3B, NDUFA5, SDHD, DCTN2, PLCG1, PRKCA, MAPK14, PPID, CALM1 | More | | | Doxapram | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | | Doxapram | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | | Doxapram | hsa05110 | Vibrio cholerae infection | 1.98E-02 | 3 | Q13488, P17252, P19174 | TCIRG1, PRKCA, PLCG1 | More | | | Doxapram | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.85E-03 | 5 | Q16539, P09341, P25024, P25025, P07948 | MAPK14, CXCL1, CXCR1, CXCR2, LYN | More | | | Doxapram | hsa05132 | Salmonella infection | 3.94E-05 | 13 | P25963, P08238, Q9UJU2, O00471, Q13546, Q13489, P04406, O75369, Q13561, O60282, Q13509, P68371, P49754 | NFKBIA, HSP90AB1, LEF1, EXOC5, RIPK1, BIRC3, GAPDH, FLNB, DCTN2, KIF5C, TUBB3, TUBB2C, VPS41 | More | | | Doxapram | hsa05133 | Pertussis | 2.60E-04 | 2 | P0DP23, P0C0L4 | CALM1, C4A | More | | | Doxapram | hsa05135 | Yersinia infection | 4.65E-02 | 5 | P13612, P06239, Q16539, P01375, P49841 | ITGA4, LCK, MAPK14, TNF, GSK3B | More | | | Doxapram | hsa05140 | Leishmaniasis | 6.62E-06 | 14 | P13612, O75015, P14598, P23458, P42224, P13765, O60603, P25963, P01375, P01584, P29350, P49006, Q16539, Q15080 | ITGA4, FCGR3B, NCF1, JAK1, STAT1, HLA-DOB, TLR2, NFKBIA, TNF, IL1B, PTPN6, MARCKSL1, MAPK14, NCF4 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P13612 | ITGA4 | Integrin alpha-4 | -0.797 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.92 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.814 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | P14598 | NCF1 | Neutrophil cytosol factor 1 | -0.867 | | P09960 | LTA4H | Leukotriene A-4 hydrolase | P14598 | NCF1 | Neutrophil cytosol factor 1 | 0.798 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 0.757 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | -0.912 | | P09960 | LTA4H | Leukotriene A-4 hydrolase | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.787 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.785 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.754 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O60603 | TLR2 | Toll-like receptor 2 | 0.842 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O60603 | TLR2 | Toll-like receptor 2 | 0.73 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | -0.739 | | P09960 | LTA4H | Leukotriene A-4 hydrolase | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.768 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01584 | IL1B | Interleukin-1 beta | 0.807 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | P29350 | PTPN6 | Tyrosine-protein phosphatase non-receptor type 6 | -0.797 | | P09960 | LTA4H | Leukotriene A-4 hydrolase | P29350 | PTPN6 | Tyrosine-protein phosphatase non-receptor type 6 | 0.808 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P49006 | MARCKSL1 | MARCKS-related protein | -0.852 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.883 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 1 | | Q13370 | PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Q15080 | NCF4 | Neutrophil cytosol factor 4 | -0.723 | | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q15080 | NCF4 | Neutrophil cytosol factor 4 | 0.762 | | P09960 | LTA4H | Leukotriene A-4 hydrolase | Q15080 | NCF4 | Neutrophil cytosol factor 4 | 0.758 |
| | Doxapram | hsa05143 | African trypanosomiasis | 1.11E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | | | Doxapram | hsa05144 | Malaria | 1.50E-05 | 8 | P60033, P69905, P68871, O60603, P01375, P35443, P01584, P26718 | CD81, HBA2, HBB, TLR2, TNF, THBS4, IL1B, KLRK1 | More | | | Doxapram | hsa05146 | Amoebiasis | 5.89E-04 | 11 | P01584, P09341, P19875, P14778, P27930, P01375, O60603, P05089, P30679, P22694, P08311 | IL1B, CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, ARG1, GNA15, PRKACB, CTSG | More | | | Doxapram | hsa05150 | Staphylococcus aureus infection | 1.31E-02 | 2 | P0C0L4, P13646 | C4A, KRT13 | More | | | Doxapram | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | | Doxapram | hsa05163 | Human cytomegalovirus infection | 1.87E-03 | 10 | P01375, P63218, P50151, Q14643, P49841, P14778, P25025, Q16539, P04637, O00463 | TNF, GNG5, GNG10, ITPR1, GSK3B, IL1R1, CXCR2, MAPK14, TP53, TRAF5 | More | | | Doxapram | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 4.19E-05 | 14 | P01568, P42224, P25963, P40189, P23458, P62873, P62879, P19174, Q13469, P16298, Q02750, P04141, P0DP23, P0CG47 | IFNA21, STAT1, NFKBIA, IL6ST, JAK1, GNB1, GNB2, PLCG1, NFATC2, PPP3CB, MAP2K1, CSF2, CALM1, UBB | More | | | Doxapram | hsa05168 | Herpes simplex virus 1 infection | 5.08E-05 | 15 | P25963, P01568, Q05823, Q9GZY0, P42224, Q07955, Q01130, Q13243, Q13489, Q13398, Q9HCX3, Q03923, P52738, O75820, Q9UDV6 | NFKBIA, IFNA21, RNASEL, NXF2; NXF2B, STAT1, SFRS1, SFRS2, SFRS5, BIRC3, ZNF211, ZNF304, ZNF85, ZNF140, ZNF189, ZNF212 | More | | | Doxapram | hsa05170 | Human immunodeficiency virus 1 infection | 6.02E-03 | 5 | Q02750, P62879, P16298, Q05397, P20333 | MAP2K1, GNB2, PPP3CB, PTK2, TNFRSF1B | More | | | Doxapram | hsa05171 | Coronavirus disease - COVID-19 | 1.36E-02 | 7 | P25963, P42224, P01568, P40189, P04141, P19174, P17252 | NFKBIA, STAT1, IFNA21, IL6ST, CSF2, PLCG1, PRKCA | More | | | Doxapram | hsa05200 | Pathways in cancer | 1.75E-02 | 14 | P08238, P42224, P25963, P19174, P17252, P43246, P14923, P49767, Q12778, P62873, O75293, P0DP23, P01568, P40189 | HSP90AB1, STAT1, NFKBIA, PLCG1, PRKCA, MSH2, JUP, VEGFC, FOXO1, GNB1, GADD45B, CALM1, IFNA21, IL6ST | More | | | Doxapram | hsa05202 | Transcriptional misregulation in cancer | 6.59E-03 | 15 | P17844, P14780, P27930, Q16548, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, P41182, Q13547, Q92769, P12980, P24522 | DDX5, MMP9, IL1R2, BCL2A1, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, HDAC1, HDAC2, LYL1, GADD45A | More | | | Doxapram | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | | Doxapram | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | | Doxapram | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | | Doxapram | hsa05206 | MicroRNAs in cancer | 2.97E-03 | 6 | P15311, P21860, P61978, P46531, P63279, P22105 | VIL2, ERBB3, HNRPK, NOTCH1, UBE2I, TNXB | More | | | Doxapram | hsa05212 | Pancreatic cancer | 4.16E-02 | 2 | Q15311, P23458 | RALBP1, JAK1 | More | | | Doxapram | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | | | Doxapram | hsa05214 | Glioma | 1.09E-02 | 4 | P0DP23, P17252, P19174, O75293 | CALM1, PRKCA, PLCG1, GADD45B | More | | | Doxapram | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | | | Doxapram | hsa05217 | Basal cell carcinoma | 7.91E-03 | 5 | Q13635, P04628, P49841, Q9UJU2, P24522 | PTCH1, WNT1, GSK3B, LEF1, GADD45A | More | | | Doxapram | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | | Doxapram | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | | | Doxapram | hsa05224 | Breast cancer | 4.75E-02 | 4 | P49841, Q92837, P04637, P24522 | GSK3B, FRAT1, TP53, GADD45A | More | | | Doxapram | hsa05225 | Hepatocellular carcinoma | 1.85E-02 | 2 | Q92529, P51531 | SHC3, SMARCA2 | More | | | Doxapram | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | | | Doxapram | hsa05231 | Choline metabolism in cancer | 2.25E-03 | 5 | Q9NRA1, Q9Y259, P19174, P23743, P17252 | PDGFC, CHKB, PLCG1, DGKA, PRKCA | More | | | Doxapram | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.34E-05 | 16 | P25963, O95267, P19174, P07766, P20963, P09693, P06239, P29350, P23458, P42224, O60603, P10747, Q04759, Q16539, Q9HC35, P01730 | NFKBIA, RASGRP1, PLCG1, CD3E, CD247, CD3G, LCK, PTPN6, JAK1, STAT1, TLR2, CD28, PRKCQ, MAPK14, EML4, CD4 | More | | | Doxapram | hsa05321 | Inflammatory bowel disease | 7.47E-04 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, P01584 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL1B | More | | | Doxapram | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | | Doxapram | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Doxapram | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | | | Doxapram | hsa05340 | Primary immunodeficiency | 1.28E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | | | Doxapram | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 2.17E-03 | 1 | P54284 | CACNB3 | More | | | Doxapram | hsa05414 | Dilated cardiomyopathy | 4.55E-02 | 2 | P54284, P26678 | CACNB3, PLN | More | | | Doxapram | hsa05415 | Diabetic cardiomyopathy | 1.87E-05 | 8 | P17252, P14598, Q15080, Q16718, O14521, Q16539, P49841, P04406 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, MAPK14, GSK3B, GAPDH | More | | | Doxapram | hsa05418 | Fluid shear stress and atherosclerosis | 2.64E-03 | 7 | Q16539, P10599, P14780, P01375, P04637, P14778, P27930 | MAPK14, TXN, MMP9, TNF, TP53, IL1R1, IL1R2 | More | |
|
